Daniel Carlat, MD

Clinical Guidance

Example of a Modified Finnegan Neonatal Abstinence Score

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Example of a Modified Finnegan Neonatal Abstinence Score

Clinical Guidance

How to Manage and Taper Buprenorphine

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

After you have initiated buprenorphine, see patients weekly at first to make sure the dose is right.

Clinical Guidance

How to Discuss and Initiate Extended-Release Naltrexone (Vivitrol)

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Extended-release naltrexone injection (XR-NTX) is an effective medication for some patients with opioid use disorder (OUD).

Clinical Guidance

How to Discuss and Initiate Buprenorphine

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Induction refers to the process of starting a patient on buprenorphine (with or without naloxone; the combination product is most often preferred).

Clinical Guidance

How to Choose the Right Medications for Opioid Use Disorder

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

The purpose of this fact sheet is not to provide details on pharmacology or the use of these medications, but rather to help you decide which might be best for a given patient.

Clinical Guidance

Clinical Opiate Withdrawal Scale

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

The Clinical Opiate Withdrawal Scale (COWS) is an 11-item scale designed to be administered by a clinician.

Clinical Guidance

Practical Tips for Using the Clinical Opiate Withdrawal Scale (COWS)

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

The Clinical Opiate Withdrawal Scale (COWS) is an 11-item scale used for rating the degree of opioid withdrawal.

Clinical Guidance

Opioid Withdrawal: Time Course and Symptoms

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

It’s hard to predict whether a particular person will experience withdrawal or how severe their symptoms will be.

Clinical Guidance

Opioid Withdrawal Management

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Getting patients with opioid use disorder (OUD) completely off opioids, so-called “detox,” is generally not advisable.

Clinical Guidance

How to Ask DSM-5 Focused Questions for Opioid Use Disorder

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Like all substance use disorders, opioid use disorder (OUD), defined by the DSM-5, includes 11 criteria.